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ERPS has been applied to 837 medicines. 576 medicines (69% of those analyzed) had 
a national average price higher than IRP and had some market power, and therefore 
their prices were regulated. They represent 80% of public expenditure in medicines 
not covered by the basic health care plan. The average price reduction for those 
medicines was 40%. 1) a) SCC between HHI and APR is -0,01,. and 2) SCC between 
number of competitors in a relevant market and APR is -0,05. ConClusions: EPRS 
could represent important savings to Colombian Health System. Deeper analysis on 
SCC is needed in order to improve ERPS. Nonetheless, preliminary analysis suggests 
that other variables besides HHI, such as countries with better purchasing practices, 
therapeutic class, types of diseases, should be taken into account.
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objeCtives: Herb-drug interactions are an important safety concern. This study 
was conducted regardingthe interaction between the herbal remedy Rosmarinus 
officinalis essential oil and drugs which metabolism involves cytochrome P450 
isoenzymes. Major components of essential oil of the rosemary are monoterpene 
derivatives(1,8-cineole, camphor, α -pinene, β -pinene, camphene, borneol and 
limonene) which selectively induce cytochrome P450 activity. The influence of 
Rosmarinus officinalis essential oil on pharmacodynamic effects of diazepam and 
pentobarbital on experimental animals was evaluated in the study. Methods: The 
study was performed on NMRI-Haan mice, which were divided into control and 
experimental groups, each group consisted of 6 animals. The experimental groups 
were pretreated with the essential oil in a dose of 10 µl/kg and 20 µl/kg, applied 
orally, as a single and seven-days lasting pretreatment. Control was treated with 
saline 10 ml/kg, orally. Interaction with pentobarbital was examined by pentobarbi-
tal-induced sleeping time test (pentobarbital was administered intraperitoneally, 40 
mg/kg b.w.). The interaction with diazepam was examined by rotarod test (diazepam 
was administered intramuscularly, 2,5 mg/kg b.w.). Results: Seven-days pretreat-
ment with Rosmarinus officinalis essential oil in the dose of 10 µl/kg, significantly 
reduced pentobarbital-induced sleeping time, compared to the control group, 
p< 0.05, while the single-dose pretreatment with Rosmarinus officinalis essential 
oil in the dose of 20 µl/kg, significantly prolonged sleeping time, compared to the 
control, p< 0.05. Both doses of essential oil, applied repeatedly, caused significantly 
longer retention of mice on the rotarod in the period between the fifth and tenth 
minute after the administration of diazepam, compared to the group received diaz-
epam only (control), p< 0.05. ConClusions: The results have shown a considerable 
influence of Rosmarinus officinalis essential oil on diazepam and pentobarbital 
pharmacodynamics, and the ability of this herbal remedy to cause interaction with 
conventional drugs.
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objeCtives: While the utilization of National Health Insurance (NHI) covered 
Chinese medications (CMs) increased for the past one decade, this study aimed to 
evaluate the use of high alert Chinese Medications (HACMs) and its contributing 
factors in Taiwan. Methods: The six potential HACMs (Màn Tuó Luó, Qi¨°n Niú 
Z¨«, Chu¨°n W¨±, Ti¨°n Nán X¨©ng, Fù Z¨«, Bàn Xià) were selected upon the evidence-
based reviews and expert discussions. The retrospective cohort study was conducted 
using two million random samples of Taiwan National Health Insurance Research 
Databases (NHIRDs). The number of prescriptions, average durations, and average 
doses for these six HACMs across different levels of hospitals (clinics, district hospi-
tals, regional hospitals, medical centers) were compared using descriptive statistics 
and ANOVA. The inferential analyses using Chi-square, t and logistic regression 
tests were performed to explore the factors associated with the use of specified 
HACMs. Results: Of 420,637 patients ever prescribed with CMs in 2007, 9.2% were 
ever prescribed with the six specified potential HACMs. While the average duration 
was 16.6±23.6 days for all HACM users, the most common used HACMs were Bàn Xià 
and Fù Z¨«. The traditional Chinese Medicine (TCM) clinics prescribed the majority of 
HACMs (90.8%) and their average doses were statistically significant higher than that 
in hospital settings. Those who were female, aged 65-74 year-old, middle income, 
with 10 to 39 more items of outpatient prescribed medications, with severe hepatic 
disorders and located in north region of Taiwan tended to use these HACMs, while 
those located in central region of Taiwan, made outpatient visits more than 2 times 
and more than 40 items of prescribed medications, and with chronic pulmonary 
diseases were less likely to use these HCAMs. ConClusions: While the TCM clinics 
tended to prescribed HACMs, more attention should be made toward them as well 
as those who possessed specific characteristics.
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objeCtives: To compare persistence among patients with infusion (IV) vs. sub-
cutaneous (SQ) biologic claims stratified by indication. Methods: This retrospec-
tive, observational analysis used national data from Symphony Health Solutions 
(SHS). Adults with their first (index) IV or SQ biologic claim (excluding rituximab) 
from July 2, 2009 to January 8, 2010, were identified. Proxy eligibility criteria included 
Surgery (726.7 days), Ophthalmic (487.6 days) and Gastroenterology/Urology (482.2 
days). Among the product categories “Ruibetsu” in Japan, the standard deviation of 
regulatory review time was the smallest for Tube and Catheters (348.5 days) and the 
largest in orthopedics products (769.6 days). ConClusions: According to the data 
analysis the review time and standard deviation of PMA and New Medical Device 
between two countries had no significant difference. Both in the United States and 
Japan, certain category medical device approval timing predictability is low such as 
General&Plastic Surgery in US and orthopedics products in Japan.
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objeCtives: Recent decision suggested that regulatory bodies, especially European 
Medicines Agency (EMA), might be more open to risk management, while payers, 
show high risk aversion, especially with drug prices increasing. The objective of the 
project was to document the potential antagonism between regulators and payers 
in Europe, illustrated by specific examples of market access decisions. Methods: 
A review of drugs which obtained a marketing authorization (MA) between 2010 and 
2012, and were subjected to a higher scrutiny by regulators and payers (oncology 
drugs, orphan drugs, drugs which received a conditional marketing authorization), 
was performed. Overall, five drugs (ipilimumab, ofatumumab, pixantrone, pirfeni-
done, abiraterone acetate) were selected and analyzed at EMA level and at payer 
level in 7 EU countries: France, the UK, Germany, Italy, Spain, The Netherlands and 
Sweden, for available public reports. Results: The EMA, despite not compelling 
evidence, considered the potential benefit of the drug to be outstanding enough 
to justify a MA provided the manufacturer is running specific additional clinical 
research (e.g. ofatumumab, pixantrone, pirfenidone). Payers require harder evidence 
than regulators, evidence of benefit for primary endpoints such as overall survival, 
comparative data with adequate comparator, robustness of methodology, effect 
size, transferability to clinical practice, etc. Overall, there were 2 ‘not recommended’ 
decisions, 3 ‘restricted’ approvals, 3 financial agreements and 1 pay for performance 
scheme that were identified at payers’ level. ConClusions: The development of 
risk management strategies allowed the product to rapidly obtain a MA. However, 
payers’ high risk aversion was a hurdle for market access of new drugs, delaying 
patient access to new therapy even with the use of some instruments such as 
conditional reimbursement.
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objeCtives: Prescription drug monitoring programs (PDMPs) are viewed as an 
effective tool to reduce prescription drug abuse, diversion, and doctor shopping. 
Despite perceived effectiveness, PDMP utilization by health care providers remains 
low. To improve effectiveness, health care professionals must access and utilize 
PDMP reports when making treatment decisions. Understanding characteristics of 
PDMPs users may assist in developing strategies to increase utilization. We identify 
characteristics of community pharmacists in Kentucky who utilize the Kentucky 
All Schedule Prescription Electronic Reporting (KASPER) program and determine if 
perceptions regarding KASPER’s impact and effectiveness are related to pharmacists’ 
characteristics. Methods: Surveys were mailed to 2,018 Kentucky pharmacists. 
Reminder postcards and surveys were sent two weeks after the initial mailing. 
Bivariate analyses examined relationships between respondent characteristics 
and practice site (independent versus chain) and practice location (rural versus 
urban). Logistic regression models (LRM) adjusted for years since licensure, con-
trolled substance (CS) dispensing volume, and perceived KASPER effectiveness 
estimated the odds ratio (OR) and 95% confidence intervals (CI) of KASPER utili-
zation by community pharmacists. Statistical analyses were conducted in Stata 
v12.0. The study was approved by the University of Kentucky Institutional Review 
Board. Results: Responses from 411 community pharmacists were included in the 
analysis. Results from LRM show that KASPER use varies significantly. Community 
pharmacists practicing in urban locations are 2.25 times more likely (CI: 1.11-4.57) 
to utilize KASPER than pharmacists in rural locations. Additionally, pharmacists 
practicing at independent pharmacies are 7.60 times more likely (CI: 3.20-18.05) to 
use KASPER than their counterparts practicing at chain pharmacies. The volume of 
CS dispensed nor perceived effectiveness of KASPER influenced the odds of KASPER 
utilization. ConClusions: Among community pharmacists, KASPER utilization 
varies and is influenced by pharmacists’ characteristics including practice site and 
practice location. Understanding characteristics of pharmacists who utilize PDMPs 
is necessary to remove barriers to access and increase utilization.
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bACkgRound: Very high prices of medicines have been observed in Colombia com-
pared to other countries; hence, a new external reference pricing system (ERPS) was 
adopted in 2013. ERPS includes three main phases: 1) Identification of relevant mar-
kets; 2) Analysis of market power using the Hirschman-Herfindahl index (HHI); and 
3)Setting-up of an international reference price (IRP) for each relevant market, using 
available information of wholesaler prices of 17 countries from the Americas, Europe 
and Australia. objeCtives: To evaluate Colombia’s EPRS. Methods: The ERPS will 
be evaluated through two different tools: 1) Through its impact on public health 
expenditure on medicines, and number of medicines regulated, and 2) Through 
the simple correlation coefficient (SCC) between a) HHI and average price reduction 
(APR), and b) Number of competitors in a relevant market and APR. Results: 1) 
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sideration if the duals are treated as a homogenous group. The objective of this study 
was to compare elderly vs disabled duals across demographic, morbidity, health 
care utilization, and drug spending measures. Methods: Cross-sectional analysis 
comparing profiles of disabled (n= 90,894) and elderly (n= 126,752) fee-for-service 
beneficiaries with continuous 12-month dual-eligibility, or until alive in the 2007 
5% Medicare files. Chi-square and t-tests were conducted to measure statistically 
significant differences across measures of interest between elderly and disabled 
duals. Results: Elderly duals were more likely to be female and suffer from chronic 
conditions like CHF, while disabled duals were more likely to have mental disorders 
like depression. Disabled duals had significantly higher rates of ER use (8.4% vs 6.4%) 
and lower rate of hospitalization (31.9% vs 24.5%) than elderly duals. Compared to 
the disabled, elderly duals had significantly higher rates of Part D brand drug use 
(88% vs 81%), but lower use of drugs typically placed on Part D specialty tiers (10% 
vs 13%). Significant differences existed in the types of drug classes frequently used 
by the two groups. Large differences in spending across all types of medical services 
and drug categories across the two groups were observed. ConClusions: There 
are significant differences in demographic, morbidity, health care utilization, and 
drug spending measures across the elderly vs. disabled duals. Recognizing the dif-
ferences between sub-populations of dual eligibles is critically important and a “one 
size fits all” approach may unintentionally create hardships and be detrimental to 
the well-being of the duals.
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objeCtives: (1) To examine the impact of two medication review programs designed 
to decrease overall health care costs through optimizing medication therapy. The 
interventions are designed to promote proper prescribing in accordance with clini-
cal literature and national guidelines and counsel individual members with regard 
to their medication regimens; (2) To explore the use of randomized clinical trials 
to vet vendor proposed programs for improving health and reducing health care 
costs. Methods: Independence Blue Cross and their Pharmacy Benefit Manager, 
Catamaran jointly designed a randomized controlled trial to test the efficacy of 
two medication review programs. Medical and pharmacy claims data for members 
assigned to the intervention condition were analyzed daily for intervention opportu-
nities based on a complex set of rules. The rules identify members who may benefit 
from one or more of 14 potential therapy adjustments including drug-drug and 
drug-condition interactions, dose optimization, appropriateness of therapy, high 
risk medication in the elderly, and generic interchange. Once identified, Catamaran 
contacted prescribers via fax to recommend therapy adjustments. Verification of 
therapy changes were determined through claims reviews and prescriber feed-
back. Results: 39,138 members were randomly assigned to either the intervention 
or control. Results show that 28% of the clinical recommendations were adopted 
resulting in a reduction in pharmacy spend of $72,747 and a reduction in medi-
cal spend of $1 million. ConClusions: Catamaran’s medication review programs 
show significant medical and pharmacy cost savings while improving population 
health through appropriate management of prescription drugs. These programs 
are intended to help members avoid inappropriate or potentially dangerous medi-
cations, increase medication adherence, close gaps in care, optimize medication 
therapy, and lower medical costs. Moreover, we demonstrate that a collaborative 
approach to evaluating a proposed vendor solution resulted in a cost effective RCT 
that offers maximum benefit to members and the health plan.
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exPenDItures anD PHarmacy reImbursement rates (2010-2012)
Balkhi B.1, Alshehri A.1, Szeinbach S.L.2, Seoane-Vazquez E.1
1International Center for Pharmaceutical Economics and Policy, Massachusetts College of 
Pharmacy and Health Sciences, Boston, MA, USA, 2Ohio State University, Columbus, OH, USA
objeCtives: This study assessed trends in state-level, fee-for-service Medicaid 
generic and brand drug utilization and expenditures, and pharmacy reimburse-
ment rates in the period 2010-2012. Methods: Medicaid fee-for-service outpatient 
pharmacy utilization and expenditures, and reimbursement rates (ingredient cost 
and dispensing fees) for the years 2010-2012 were extracted from State-level data 
provided from the Centers for Medicare and Medicaid Services. Current dollars 
were converted to 2012 dollars using the U.S. consumer price index. Descriptive 
analyses were performed for all variables. Confidence intervals (95%) were calcu-
lated for continuous variables. Linear regression analysis was performed to assess 
the relationship between ingredient cost, dispensing fees and drug utilization. The 
significance level for variables was 0.05. Results: Fee-for-service Medicaid expen-
ditures (n= 42 states) decreased from $23.0 billion in 2010 to $18.7 billion in 2012 
(14.9% decrease) and drug utilization decreased from 351.2 to 281.4 million claims 
in the same period (19.9% decrease). Generic utilization represented 70.6% of total 
prescriptions in 2010 and 75.4% in 2012, and generic expenditures represented 17.9% 
of total expenditures in 2010 and 18.0% in 2012. The average reimbursement of 
generic drugs was $17.89 (95%CI= $16.63-$19.14) in 2010 and decreased to $16.91 
(95%CI= $14.48-$19.34) in 2012, while the average reimbursement of brand drugs 
increased from $197.34 (95%CI= $184.74-$209.94) to $235.93 (95%CI= $218.07-$253.79). 
The average pharmacy dispensing fee increased from $4.34±$1.24 to $4.60±$2.56 
for generics and from $4.10±$1.19 to $4.38±$2.58 for brands. We found no statis-
tically significant relationship between the number of claims or the total state 
expenditures, and the dispensing fee or the average ingredient cost. ConClusions: 
Pharmacy expenditures decreased in the period 2010-2012 due to a decrease in the 
volume of prescriptions and the reduction in generic prices. Differences in dispens-
ing fees and ingredient costs among Medicaid programs were independent of total 
prescription volume. Increases in generic utilization could result in substantial 
savings to Medicaid programs.
complete claims 180 days pre and 720 days post index. Biologic claim clean period 
was 180 days pre-index. SQ biologic users with reported days supplies that were 
< 7 or > 90 days were excluded. Duration of action for infusion products was based 
on package inserts. Patients were censored after a gap of at least 90 days beyond 
the next expected re-fill interval. Results describe median time to discontinuation 
(Kaplan-Meier plots) covering 720 days. A Cox regression model assessed the IV vs 
SQ hazard ratio. Results: 1830 IV and 5934 SQ patients were identified. Diagnoses 
in the IV cohort included 29.9% IBD, 50.4% RA, 3.2% PsA and 16.5% any combination 
or none. Corresponding diagnoses for the SQ cohort were 10.9%, 49.5%, 8.9% and 
30.7% respectively. IV and SQ cohorts were similar for gender and co-morbidities, 
and IV cohort was slightly older with slightly higher use of concomitant methotrex-
ate and steroids than SQ cohort in RA and PsA. Overall, median time to discontinu-
ation for IV was 388 days vs SQ at 191 days, and was significantly longer for IV vs 
SQ across all indications. Within SQ cohort, RA patients (203 days) had the longest 
persistence vs other indications. For IV cohort, it was PsA patients (471 days). IBD 
patients tended to have the shortest persistence. Cox regression showed hazard for 
SQ discontinuation 1.61(CI:1.51-1.72) times greater than for IV, controlling for age, 
gender and co-morbidities. ConClusions: IV consistently demonstrated longer 
times to discontinuation vs. SQ across indications studied.
PHP37
examInIng tHe effect of PHarmacIsts’ vIsIts to HomebounD PatIents 
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objeCtives: This study sought to examine the effect of pharmacists’ visits to home-
bound patients on the elimination of unused drugs. Methods: We conducted a 
survey with pharmacies throughout Japan that provided home visiting service, 
requesting their home-visiting pharmacists to respond to questions regarding 
their work with up to five homebound patients (the survey period was January 15, 
2013 through the end of February, 2013). Main survey questions were: (1) have you 
handled unused drugs since the home visits started? and (2) how did you handle 
the unused drugs? For (2), we conducted case studies by asking the pharmacists 
to choose the case that impressed them most and describe chronologically the 
unused drugs involved, the action taken, and what followed the action. Results: 
Data on 5,447 patients was collected from 1,890 pharmacies throughout Japan (col-
lection rate: 56.9%). Pharmacists handled unused drugs of 2,484 patients (45.6%). 
1,718 patients (3,593 cases) were qualified for analysis. In 2,334 cases (65%), the 
incidences of unused drugs were eliminated after pharmacists’ intervention. In 
782 cases (21.8%), unused drugs were discarded, while in 2,624 cases (73.0%), the 
number of days of drug administration was adjusted. In 21 cases (0.6%), drugs were 
both discarded and had the number of days adjusted. There were no responses 
for 166 cases (4.6%). The total price of the unused drugs that were eliminated was 
approximately 6,800,000 yen (4,000 yen/person). The top three illnesses with the 
best effects from the elimination of unused drugs were chronic respiratory failure 
(approximately 16,500 yen/person), Parkinson’s disease (approximately 5,000 yen/
person), and cancer (approximately 4,300 yen/person). ConClusions: We were 
able to confirm the economic effect of eliminating unused drugs by pharmacists’ 
home visits.
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objeCtives: This analysis examined potential risk factors for adverse drug reac-
tion (ADR)-related hospitalizations and compared seniors’ drug therapy pre-
admission and post-discharge to see whether hospitalization led to changes in 
drug therapy. Methods: This analysis used hospital discharge data from the 
Discharge Abstract Database and drug claims data from the National Prescription 
Drug Utilization Information System Database to assess potential risk factors for 
ADR hospitalizations among seniors on public drug programs in Alberta, Manitoba 
and P.E.I. Results: The number of drugs was the most significant risk factor, with 
seniors taking 15 or more drugs 6.4 times more likely than seniors taking fewer 
than 5 drugs to have been hospitalized for an ADR. Other factors associated with 
hospitalizations for ADRs were patient age and being hospitalized in the previous 
year. The relationship between new drug starts and ADR-related hospitalizations 
varied by drug class. 33.2% of seniors hospitalized for an opioid-related ADR started 
taking an opioid within 30 days of hospitalization, while only 28.2% of seniors hos-
pitalized for an anticoagulant-related ADR started an anticoagulant within a year of 
hospitalization. ConClusions: Although it is often necessary for seniors to take 
multiple drugs to manage their chronic conditions, regular medication reviews can 
help reduce the risk of adverse events including drug interactions. A high proportion 
of the hospitalizations related to anticoagulant ADRs occurred more than a year 
after starting therapy, which underscores the importance of ongoing monitoring.
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objeCtives: Dual-eligibles are elderly and disabled under age 65 individuals who 
are entitled to Medicare and Medicaid. CMS has instituted a state demonstration 
program to test capitated and managed FFS financial alignment care models for 
duals. Limited research exists on the differences between the two dual subpopula-
tions – elderly and disabled, which could prove problematic for benefit design con-
